276 related articles for article (PubMed ID: 16299278)
1. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.
Park HS; Cleary PP
Infect Immun; 2005 Dec; 73(12):7878-86. PubMed ID: 16299278
[TBL] [Abstract][Full Text] [Related]
2. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus.
Ji Y; Carlson B; Kondagunta A; Cleary PP
Infect Immun; 1997 Jun; 65(6):2080-7. PubMed ID: 9169735
[TBL] [Abstract][Full Text] [Related]
4. Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.
Chen X; Li N; Bi S; Wang X; Wang B
PLoS One; 2016; 11(12):e0168861. PubMed ID: 28030629
[TBL] [Abstract][Full Text] [Related]
5. Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci.
Fan X; Wang X; Li N; Cui H; Hou B; Gao B; Cleary PP; Wang B
PLoS One; 2014; 9(9):e107638. PubMed ID: 25232948
[TBL] [Abstract][Full Text] [Related]
6. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus.
Park HS; Francis KP; Yu J; Cleary PP
J Immunol; 2003 Sep; 171(5):2532-7. PubMed ID: 12928403
[TBL] [Abstract][Full Text] [Related]
7. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development.
Shet A; Kaplan EL; Johnson DR; Cleary PP
J Infect Dis; 2003 Sep; 188(6):809-17. PubMed ID: 12964111
[TBL] [Abstract][Full Text] [Related]
8. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
[TBL] [Abstract][Full Text] [Related]
9. Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections.
Shet A; Kaplan E; Johnson D; Cleary PP
Indian J Med Res; 2004 May; 119 Suppl():95-8. PubMed ID: 15232171
[TBL] [Abstract][Full Text] [Related]
10. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine].
Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA
Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000
[TBL] [Abstract][Full Text] [Related]
11. Toll-like Receptors 2 and 4-Mediated Reciprocal Th17 and Antibody Responses to Group A Streptococcus Infection.
Wang X; Fan X; Bi S; Li N; Wang B
J Infect Dis; 2017 Feb; 215(4):644-652. PubMed ID: 28011917
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
13. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model.
McArthur J; Medina E; Mueller A; Chin J; Currie BJ; Sriprakash KS; Talay SR; Chhatwal GS; Walker MJ
Infect Immun; 2004 Dec; 72(12):7342-5. PubMed ID: 15557665
[TBL] [Abstract][Full Text] [Related]
14. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase.
Santillan DA; Andracki ME; Hunter SK
Am J Obstet Gynecol; 2008 Jan; 198(1):114.e1-6. PubMed ID: 17905172
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice.
Yokoyama Y; Harabuchi Y
Int J Pediatr Otorhinolaryngol; 2002 May; 63(3):235-41. PubMed ID: 11997159
[TBL] [Abstract][Full Text] [Related]
18. The early interferon response of nasal-associated lymphoid tissue to Streptococcus pyogenes infection.
Hyland KA; Brennan R; Olmsted SB; Rojas E; Murphy E; Wang B; Cleary PP
FEMS Immunol Med Microbiol; 2009 Apr; 55(3):422-31. PubMed ID: 19243434
[TBL] [Abstract][Full Text] [Related]
19. Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase.
Lynskey NN; Reglinski M; Calay D; Siggins MK; Mason JC; Botto M; Sriskandan S
PLoS Pathog; 2017 Aug; 13(8):e1006493. PubMed ID: 28806402
[TBL] [Abstract][Full Text] [Related]
20. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
